ClinicalTrials.gg
CompletedNCT02563054Updated Nov 2, 2016

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

A Phase 3 interventional study of 5-Fluorouracil and Capecitabine in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 45 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.

Enrollment
12th of 97
316 · median 50
Started
2003
with 2 others
Phase 3
17 of 100
4 open now
Registered
78th of 100
by date
Lead sponsor
5 of 100
Hoffmann-La Roche

Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 12th largest by enrollment of the 97 interventional ones that give a count, is one of 3 that started in 2003, is one of 17 in phase 3, and was the 78th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing capecitabine in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of oral capecitabine (Xeloda) versus 5-fluorouracil (5-FU), in combination with intravenous (IV) cisplatin, in participants with advanced and/or metastatic gastric cancer. The anticipated time on study treatment is at least 6 weeks and continued up to disease progression, and the target sample size is 300 individuals.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age
  • Advanced and/or gastric cancer with at least 1

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled infection
  • Evidence of central nervous system (CNS)
  • History of other within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix
  • Radiation therapy or major surgery within 4 weeks of study drug
  • Previous chemotherapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (actual)

Study arms

  • Active comparator
    5-Fluorouracil + Cisplatin

    Participants will receive 5-FU in combination with cisplatin upto disease progression.

    Drug: 5-Fluorouracil · Drug: Cisplatin

  • Experimental
    Capecitabine + Cisplatin

    Participants will receive capecitabine in combination with cisplatin upto disease progression.

    Drug: Capecitabine · Drug: Cisplatin

Interventions

  • Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.

  • Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.

  • Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.

06

What researchers measure

Primary outcomes

  1. Time to disease progression

    Time frame: Up to approximately 7.3 years

Secondary outcomes

  1. Objective tumor response rate

    Time frame: Up to approximately 7.3 years

  2. Overall survival

    Time frame: Up to approximately 7.3 years

  3. Duration of response

    Time frame: Up to approximately 7.3 years

  4. Time to response

    Time frame: Up to approximately 7.3 years

  5. Incidence of adverse events

    Time frame: Up to approximately 7.3 years

07

Study locations

45 sites
  • Buenos Aires, C1264AAA, Argentina
  • Buenos Aires, C1270AAE, Argentina
  • Rosario, S2000PBJ, Argentina
  • Tegucigalpa, Belize
  • Barretos, 14780-400, Brazil
  • Curitiba, 80060-150, Brazil
  • Florianopolis, 88034-000, Brazil
  • Fortaleza, 60741-420, Brazil
  • Porto Alegre, 90020-090, Brazil
  • Sao Paulo, 05403-010, Brazil
  • Sorocaba, 18035-300, Brazil
  • Beijing, 100021, China
  • Beijing, 100036, China
  • Guangdong, 510060, China
  • Guangdong, 510515, China
  • Hubei, 430030, China
  • Jiangsu, 210009, China
  • Jiangxi, 330000, China
  • Shandong, 250117, China
  • Shanghai, 200003, China
  • Shanghai, 200092, China
  • Shanghai, 200433, China
  • Suzhou, 215006, China
  • Tianjin, 300060, China
  • Bogota, Colombia
  • Guatemala City, 01015, Guatemala
  • Hong Kong, 852, Hong Kong
  • Hong Kong, Hong Kong
  • Seoul, 135-170, Korea, Republic of
  • Seoul, 135-720, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Seoul, 405-760, Korea, Republic of
  • Kuala Lumpur, 56000, Malaysia
  • Merida, 97070, Mexico
  • Mexico City, 14000, Mexico
  • Mexico City, 14080, Mexico
  • Mexico Df, 06726, Mexico
  • Panama City, 83-0669, Panama
  • Callao, Peru
  • Lima, 13, Peru
  • Kazan, 420029, Russian Federation
  • Moscow, 115478, Russian Federation
  • St Petersburg, 197758, Russian Federation
  • UFA, 450054, Russian Federation
  • Montevideo, 11600, Uruguay
08

References and documents

Publications

  • Chen J, Xiong J, Wang J, Zheng L, Gao Y, Guan Z. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial. Asia Pac J Clin Oncol. 2018 Oct;14(5):e310-e316. doi: 10.1111/ajco.12832. Epub 2018 Jan 26. PubMed 29372626 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2003, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2015
First posted
Sep 29, 2015
Start
Apr 2003
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02563054
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 29, 2015
Start date
Apr 2003
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion